 |
 |
 |
 |
 |
 |
||
 |
 |
 |
 |
 |
| 2 | 1/1 | 返回列表 |
| 查看: 713 | 回復(fù): 1 | |||
| 本帖產(chǎn)生 1 個 翻譯EPI ，點擊這里進(jìn)行查看 | |||
霜葉金蟲 (小有名氣)
|
[求助]
醫(yī)學(xué)類摘要翻譯，謝謝
|
||
|
Background: Cisatracurium in clinical practice is devoid of histamine-induced cardiovascular effects. On the other hand, 2 ED95 doses of cisatracurium (100 μ g/kg) do not create satisfactory intubating conditions such as those seen with equipotent doses of atracurium. The recommended intubating dose of cisatracurium is 3 ED95. To understand this discrepancy better, we evaluated the potency and onset of atracurium and cisatracurium. Materials and Methods: The study designed as randomized controlled clinical trial to compare between atracurium (2×ED95) and different doses of cisatracurium (2×ED95, 4×ED95, 6×ED95) regarding onset time, duration of action, condition of intubation, hemodynamic effects, and sings of histamine release clinically. Sixty four patients were randomly assigned to one of four groups, the first group (group 1) received 2×ED95 dose of atracurium, group 2 received 2×ED95 dose of cisatracurium, group 3 received 4×ED95 dose of cisatracurium, while group 4 received 6×ED95 dose of cisatracurium. The Datex relaxograph (Type NMT-100-23-01, S/N: 37541) for neuromuscular monitoring was used. Results: HR, MABP was statistically significant increased post-intubation with administration of 2×ED95 dose of atracurium in group 1 and the same dose of cisatracurium in group 2 but 5-20 min later was not statistically significant with administration of 4×ED95 and 6×ED95 doses of cisatracurium in groups 3 and 4, respectively. Onset time was found to be significantly lower with 2×ED95 dose of atracurium than with the same dose of cisatracurium. At the same time, higher doses of cisatracurium (4×ED95 and 6×ED95) showed onset time and longer duration of action that was significantly lower than with atracurium and with lower dose of cisatracurium (2×ED95). Only 6×ED95 dose of cisatracurium showed statistically significant difference versus the atracurium dose with higher percentages of patients with excellent condition of intubation. 4×ED95 and 6×ED95 doses of cisatracurium were significantly better than 2×ED95 dose of cisatracurium. 2×ED95dose of atracurium and 2×ED95 dose of cisatracurium were similar, while 4×ED95 and 6×ED95 doses of cisatracurium were significantly better than atracurium and 2×ED95 dose of cisatracurium. Conclusion: The same dose (2×ED95 dose) atracurium is more effective neuromuscular blocking agent than cisatracurium, while higher doses of cisatracurium 4×ED95 and 6×ED95 provide more effective, more rapid neuromuscular blocking with longer duration of action, stable hemodynamic status, and no associated signs of histamine release clinically. |
回復(fù)此樓» 猜你喜歡
材料求調(diào)劑 一志愿哈工大總分298分，前三科223分
已經(jīng)有5人回復(fù)
-
085600 286分 材料求調(diào)劑
已經(jīng)有6人回復(fù)
-
086502化學(xué)工程342求調(diào)劑
已經(jīng)有4人回復(fù)
-
材料求調(diào)劑一志愿哈工大324
已經(jīng)有7人回復(fù)
-
328求調(diào)劑
已經(jīng)有7人回復(fù)
-
340求調(diào)劑
已經(jīng)有5人回復(fù)
-
一志愿南昌大學(xué)324求調(diào)劑
已經(jīng)有4人回復(fù)
-
求調(diào)劑推薦 材料 304
已經(jīng)有15人回復(fù)
-
291求調(diào)劑
已經(jīng)有19人回復(fù)
-
331環(huán)境科學(xué)與工程求調(diào)劑
已經(jīng)有3人回復(fù)
RXMCDM
版主 (文壇精英)
- 翻譯EPI: 530
- 應(yīng)助: 401 (碩士)
- 貴賓: 1.908
- 金幣: 38947.6
- 散金: 4908
- 紅花: 88
- 沙發(fā): 4
- 帖子: 11453
- 在線: 1355.6小時
- 蟲號: 2739168
- 注冊: 2013-10-20
- 性別: GG
- 專業(yè): 一般管理理論與研究方法論
- 管轄: 論文翻譯
【答案】應(yīng)助回帖
★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★
霜葉: 金幣+40, 翻譯EPI+1, ★★★很有幫助, 謝謝 2013-12-02 15:53:54
霜葉: 金幣+40, 翻譯EPI+1, ★★★很有幫助, 謝謝 2013-12-02 15:53:54
|
背景： 在臨床實踐中順式-阿屈庫銨不產(chǎn)生組胺誘導(dǎo)的心血管效應(yīng)。另一方面，2 ED95（95%的有效藥物劑量）劑量順式-阿屈庫銨（100μg / kg以下）不會與等效劑量阿曲庫銨一樣產(chǎn)生滿意的插管條件。 順式-阿屈庫銨的推薦插管劑量為3 ED95。為了理解這種差異更好，我們評價阿曲庫銨和順式-阿屈庫銨的效力和起效時間。 材料和方法： 隨機(jī)對照臨床試驗，比較阿曲庫銨（2×ED95）和不同劑量順式-阿屈庫銨（2×ED95，4×ED95，6×ED95）就起效時間，作用時間，插管的狀況，血流動力學(xué)影響的研究，和有無胺釋放的臨床跡象。64個病人被隨機(jī)分成四組，第一組（第1組）接受2×ED95劑量阿曲庫銨，2組接受2×ED95劑量順式-阿屈庫銨，第3組4×ED95劑量順式-阿屈庫銨，而第4組接收6×ED95順式-阿屈庫銨劑量。該德恩relaxograph（類型NMT-100-23-01，S / N：37541）用于監(jiān)測神經(jīng)肌肉。 結(jié)果： 插管給藥2×ED95劑量阿曲庫銨的第1組和第2組相同劑量順式-阿屈庫銨HR、平均動脈壓有統(tǒng)計學(xué)顯著意義（增加）；但5-20分鐘后，分別與4×ED95組的第3組和6×ED95的第4組無統(tǒng)計學(xué)顯著性。發(fā)病時間2×ED95劑量阿曲庫銨相顯著低于同劑量的順式-阿屈庫銨。與此同時，更高的劑量順式-阿屈庫銨（4×ED95和6×ED95）的顯示發(fā)病時間和較長的作用時間比用阿曲庫銨顯和低劑量順式-阿屈庫銨（2×ED95）短�；颊叩牟骞軛l件優(yōu)越比例較高的阿曲庫銨的劑量只有6×ED95順式-阿屈庫銨的劑量與其有統(tǒng)計顯著性差異。4×ED95和6×ED95劑量順式-阿屈庫銨都顯著大于2×ED95劑量順式-阿屈庫銨。 2×ED95劑量阿曲庫銨和2×ED95劑量順式-阿屈庫銨相似，而4×ED95和6×ED95劑量順式-阿屈庫銨的比阿曲庫銨和2×ED95劑量順式-阿屈庫銨更好。 結(jié)論： 與順式-阿屈庫銨相比，相同的劑量（2×ED95劑量）阿曲庫銨是更為有效的神經(jīng)肌肉阻斷劑，而較高劑量順式-阿屈庫銨4×ED95和6×ED95提供更有效、更快速的神經(jīng)肌肉阻滯，持續(xù)時間長，穩(wěn)定的血液動力學(xué)狀態(tài)，沒有有關(guān)的組胺釋放的臨床跡象。 |
2樓2013-11-27 19:57:08
相關(guān)版塊跳轉(zhuǎn)
我要訂閱樓主 霜葉 的主題更新
| 2 | 1/1 | 返回列表 |
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 求調(diào)劑 +8 | 張zz111 2026-03-27 | 9/450 |
|
|---|---|---|---|---|
|
|
[考研] 0703一志愿9，初試成績：338，四六級已過，有科研經(jīng)歷，求調(diào)劑！ +3 | Zuhui0306 2026-03-25 | 3/150 |
|
|
|
[材料工程] 一志愿C9材料與化工專業(yè)總分300求調(diào)劑 +7 | 曼111 2026-03-24 | 8/400 |
|
|
[考研] 317求調(diào)劑 +5 | 十閑wx 2026-03-24 | 5/250 |
|
|
|
[考研] 348求調(diào)劑 +4 | 小懶蟲不懶了 2026-03-27 | 5/250 |
|
|
|
[考研] 321求調(diào)劑 +4 | 璞玉~~ 2026-03-25 | 4/200 |
|
|
|
[考研] 312求調(diào)劑 +9 | 上岸吧ZJY 2026-03-22 | 13/650 |
|
|
|
[考研]
 材料與化工考研調(diào)劑
+16
|
孅華 2026-03-22 | 16/800 |
|
|
|
[考研] 一志愿北化求調(diào)劑 +3 | Jsman 2026-03-22 | 3/150 |
|
|
|
[考研]
085602 289分求調(diào)劑
+8
|
WWW西西弗斯 2026-03-24 | 8/400 |
|
|
|
[考研] 086000生物與醫(yī)藥292求調(diào)劑 +6 | 小小陳小小 2026-03-22 | 9/450 |
|
|
|
[考研] 調(diào)劑310 +3 | 溫柔的晚安 2026-03-25 | 4/200 |
|
|
|
[考研] 一志愿上海交大生物與醫(yī)藥專碩324分，求調(diào)劑 +6 | jiajunX 2026-03-22 | 6/300 |
|
|
|
[考研] 一志愿哈工大，085400，320，求調(diào)劑 +4 | gdlf9999 2026-03-24 | 4/200 |
|
|
|
[考研] 材料與化工328分調(diào)劑 +6 | 。，。，。，。i 2026-03-23 | 6/300 |
|
|
|
[考研] 0854電子信息求調(diào)劑 +7 | α____ 2026-03-22 | 9/450 |
|
|
|
[考研] 0854電子信息求調(diào)劑 324 +4 | Promise-jyl 2026-03-23 | 4/200 |
|
|
|
[考研] 求調(diào)劑一志愿武漢理工大學(xué)材料工程（085601） +5 | WW.' 2026-03-23 | 7/350 |
|
|
|
[考研] 求調(diào)劑 +5 | Zhangbod 2026-03-21 | 7/350 |
|
|
|
[考研] 一志愿深大，0703化學(xué)，總分302，求調(diào)劑 +4 | 七月-七七 2026-03-21 | 4/200 |
|